Navigation Links
Drug Fails to Slow Progression of Atherosclerosis
Date:3/17/2009

Pactimibe also was associated with more risk of major heart problems, study finds

TUESDAY, March 17 (HealthDay News) -- A drug that blocks an enzyme involved in the accumulation of cholesterol does not reduce the progression of atherosclerosis, thickening and stiffening of the arteries, but increases the risk of major cardiovascular events, according to an international study.

Researchers assessed the safety and efficacy of the drug pactimibe, which inhibits an enzyme known as ACAT, in 892 people with a family history of high cholesterol, which is associated with an increased risk of atherosclerosis. The participants, from 40 clinics in the United States, Canada, Europe, South Africa and Israel, were randomly selected to take either 100 milligrams a day of pactimibe or a placebo, in addition to standard lipid-lowering therapy.

The researchers assessed the participants' atherosclerosis at the start of the study and 12, 18 and 24 months later using ultrasound to measure carotid intima-media thickness (CIMT), a measurement of the thickness of the inner wall of a major artery. Increasing thickness indicates increasing plaque in the artery.

After six months, levels of "bad" low-density lipoprotein (LDL) cholesterol had increased by 7.3 percent among people taking pactimibe and by 1.4 percent among those taking the placebo. This increase disappeared after participants stopped taking the drug.

There was no difference between the two groups in progression of maximum CIMT, but average CIMT progressed significantly in the pactimibe group within one year, compared with minor CIMT progression in the placebo group, the study found.

Compared with people in the placebo group, those in the pactimibe group suffered more serious events (10 percent vs. 7.7 percent) and more cardiovascular events (6.3 percent vs. 3.4 percent) and had a higher rate for the composite of cardiovascular death, heart attack and stroke (2.3 percent vs. 0.2 percent).

Dr. Marijn C. Meuwese, of the Academic Medical Center in Amsterdam, The Netherlands, and colleagues wrote that in people with a family history of cholesterol, "pactimibe had no effect on atherosclerosis as assessed by changes in maximum CIMT compared with placebo but was associated with an increase in mean CIMT as well as increased incidence of major cardiovascular events."

The findings from this and previous studies lessen "the promise and further development of this class of drugs (ACAT inhibitors) for cardiovascular prevention," they concluded.

The study is in the March 18 issue of the Journal of the American Medical Association.

More information

The U.S. National Heart, Lung, and Blood Institute has more about atherosclerosis.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Federal research plan to determine nanotech risks fails to deliver
2. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Experimental Drug Fails Against Heart Failure
5. NSAID Drug Therapy Fails to Ease Back Pain
6. MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements
7. Steroid Fails to Ease Meningitis in Trials
8. Pharmaceutical market fails pregnant women; and more
9. Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
10. Post-Op Chemo Fails to Boost Survival in Stomach Cancers
11. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Fails to Slow Progression of Atherosclerosis
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology Business Management ... on current legislative activity and the latest regulatory concerns impacting RBMA members. The ... 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is ... back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh is ... partner with Cupron® to provide customers with a game changing chair that is ...
(Date:5/26/2017)... ... 2017 , ... Rob Lowe acts as host and helps educate and inform ... hiking in American. Viewers can reconnect with America as it explores some of the ... consumers have looked for an inventive new place for a family vacation, and have ...
(Date:5/26/2017)... ... ... of Eden”: retells the stories of three Bible figures in modern terms. “Just What ... trader, horse farmer, artist and a former GM journeyman. Born in 1953 in Portland, ... to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured France to ...
(Date:5/24/2017)... ... 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified ... is known for his distinguished expertise and experience in the diagnosis and treatment of ... in treating renovascular disease and aortic aneurysm . He is known for his ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
(Date:5/4/2017)... May 4, 2017 Clarius Mobile Health, ... handheld ultrasound scanners this week at the American ... (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians to ... rate, and evaluate pregnancy-related complications like ectopic pregnancy ...
(Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
Breaking Medicine Technology: